Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.36 |
| ▸ | CDA | P32320 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 2/20 | 0.33 |
| ▸ | HEXB | P07686 | 1/20 | 0.33 |
| ▸ | UMPS | P11172 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 3/20 | 0.32 |
| ▸ | TK2 | O00142 | 2/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | IL6 | P05231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15392688 | 1.00 | PYGM (0.36) | PYGMCDAPNPMEN1ALDH1A1 | |
| SCHEMBL31565646 | 0.87 | PYGM (0.41) | PYGMPNPUMPSPYGL | |
| SCHEMBL30782692 | 0.84 | CDA (0.36) | PYGMCDAMEN1ALDH1A1MAPT | |
| SCHEMBL10873399 | 0.73 | UMPS (0.39) | PYGMPNPMEN1ALDH1A1MAPT | |
| SCHEMBL10873403 | 0.73 | UMPS (0.39) | PYGMPNPMEN1ALDH1A1MAPT | |
| SCHEMBL767735 | 0.73 | CDA (0.39) | PYGMCDAPNPMEN1ALDH1A1 | |
| SCHEMBL773455 | 0.73 | CDA (0.39) | PYGMCDAPNPMEN1ALDH1A1 | |
| SCHEMBL15216151 | 0.73 | CDA (0.39) | PYGMCDAPNPMEN1ALDH1A1 | |
| SCHEMBL4300142 | 0.71 | TK1 (0.44) | SMN1; SMN2TK2 | |
| SCHEMBL30765013 | 0.70 | PYGM (0.44) | PYGMPNPALDH1A1HPGDUMPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220313697-A1 | NEK6 Inhibition to Treat ALS and FTD | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2022-10-06 | — | — | US | disclosed |
| WO-2022199804-A1 | NEK6 INHIBITION TO TREAT ALS AND FTD | VIB VZW (BE) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313697-A1 | NEK6 Inhibition to Treat ALS and FTD | NEK6, NEK11, NEK9 | PYGM 4268/4885CDA 2565/4885PNP 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.